Melinta Therapeutics, Inc. announced that the company has appointed Bruce L. Downey to its Board of Directors. Mr. Downey is an accomplished executive with over 35 years of corporate management, legal and development experience. He previously served as chairman and chief executive officer of Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company that operated in more than 30 countries worldwide and was acquired by Teva Pharmaceutical Industries Ltd. in 2008. Currently, Mr. Downey serves as a partner at NewSpring, a venture capital firm, and is a member of the board of directors of Cardinal Health, Inc., serving on the audit committee, and Momenta Pharmaceuticals, as well as privately held companies. Mr. Downey will replace Cecilia Gonzalo, who is resigning from the board following a change in principal employment that no longer permits her to sit on public company boards, including Melinta.